GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism

Table 10

Associations between CYP3A5 genotype, GRWR, and rejection status and infection.

	Rejection status				Infection
	Unadjusted OR (95% CI)	value	Adjusted OR (95% CI)	value	Unadjusted OR (95% CI)	value	Adjusted OR (95% CI)	value
Recipient CYP3A5 genotypes
Nonexpressor	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Expressor	0.997 (0.57-1.82)	0.99	0.95 (0.52-1.74)	0.86	1.376 (0.75-2.49)	0.308	1.37 (0.75-2.51)	0.305
Donor CYP3A5 genotypes
Nonexpressor	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
Expressor	1.46 (0,80-2.67)	0.21	1.33 (0.67-2.53)	0.87	1.87 (1.02-3.43)	0.043	2.04 (1.06-3.92)	0.032
GRWR
≤3%	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
>3%	1.14 (0.63-2.08)	0.66	1.01 (0.53-1.91)	0.98	1.67 (0.91-3.04)	0.095	1.78 (0.94-3.38)	0.077